Citigroup Maintains Buy on Cabaletta Bio, Lowers Price Target to $8
Reported Sunday, Cabaletta Says Rese-Cel Delivers Immunomodulator-Free Responses Across Dermatomyositis, Lupus Nephritis And Systemic Sclerosis Through At Least One Year; Myositis BLA Planned For First Quarter Of 2028
Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Cabaletta Bio Q3 EPS $(0.28) Beats $(0.33) Estimate
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cabaletta Bio to Participate in Upcoming Investor Conferences
Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns
Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Cabaletta Bio Q2 EPS $(0.34) Beats $(0.39) Estimate
How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
Cabaletta Bio Presents New Clinical Data Supporting Rese-Cel As Potential Treatment For Multiple Autoimmune Diseases, At EULAR 2026 Congress
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.